This case report details a patient with Crohn's disease (CD) who developed acute lymphoblastic leukemia (ALL) 16 years after their initial diagnosis. Various immunosuppressive therapies used in the treatment included azathioprine, infliximab and, for a short period, vedolizumab and steroids for CD and hyper-CVAD chemotherapy for leukemia. The association between CD and increased cancer risk, particularly hematological malignancies, emphasizes the importance of regular cancer surveillance, including hematological assessments, for patients on immunosuppressive therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822214 | PMC |
| http://dx.doi.org/10.7759/cureus.77400 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Therapy of Adult Patients with Acute Lymphoblastic Leukemia.
Cells
March 2025
Department of Hematology and Medical Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA.
The landscape of adult acute lymphoblastic leukemia (ALL) is dramatically changing. With very promising results seen with novel immunotherapeutics in the setting of relapsed and refractory disease, the prospect of using these agents in first-line therapy has prompted the development of multiple clinical trials addressing this question. This review seeks to outline and expand the current standard of care, as well as new advances, in the treatment of adult patients with ALL and address future areas of research.
View Article and Find Full Text PDFExpression of CD47 protein in hematolymphoid neoplasms: Implications for CD47-mediated cancer immunotherapy.
Am J Clin Pathol
March 2025
Department of Pathology, Stanford University, Stanford, CA, United States.
Objectives: Recent studies show that blocking CD47-SIRPα interactions is a promising target in checkpoint inhibition for cancer immunotherapy. However, to date, the expression of CD47 is not well characterized in various hematolymphoid neoplasms.
Methods: This study evaluates CD47 expression in a wide range of hematolymphoid neoplasms using immunohistochemistry on 834 cases.
is a Major Prognostic Biomarker for Relapse in Childhood B-cell Acute Lymphoblastic Leukemia: A National Study of Unselected Cohort.
Balkan J Med Genet
December 2024
Center for Biomolecular Pharmaceutical Analyses, Faculty of Pharmacy, University Ss. Cyril and Methodius in Skopje, Mother Theresa 47, 1000 Skopje, N. Macedonia.
Although the identification of disease subtypes conveying prognostic significance along with minimal residual disease (MRD) assessment represent cornerstones for stratification in childhood acute lymphoblastic leukemia (ALL), approximately half of the relapses occur in patients from standard-risk groups. Identification of the drivers of treatment failure is crucial for detection of high-risk clones at diagnosis. We evaluated clinical variables and the most common genetic alterations in an unselected cohort of 55 patients with B-ALL treated according to the ALL-IC-BFM 2002 protocol, with a median follow-up of 46 months.
View Article and Find Full Text PDFCo-expression of B7-H3 and LAG3 represents cytotoxicity of CD4 T cells in humans.
Front Immunol
March 2025
Department of Immunology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Recent studies have highlighted the potential contribution of CD4 T cells with cytotoxic activity (CD4 CTLs) to anti-tumor immunity. However, their precise roles remain elusive, partly due to the absence of specific markers defining CD4 CTLs with target-killing potential in humans. We previously demonstrated that Epstein-Barr virus (EBV)-driven immortalized B cell lines efficiently induce human CD4 CTLs with cytotoxic functions comparable to cytotoxic CD8 T cells (CD8 CTLs).
View Article and Find Full Text PDFFlow-cytometric MRD detection in pediatric T-ALL: a multicenter AIEOP-BFM consensus-based guided standardized approach.
Clin Chem Lab Med
March 2025
CLIP (Childhood Leukaemia Investigation Prague), Prague, Czech Republic.
Objectives: Risk-based stratification approaches using measurable residual disease (MRD) successfully help to identify T-acute lymphoblastic leukemia (T-ALL) patients at risk of relapse, whose treatment outcomes are very poor. Because of T-ALL heterogeneity and rarity, a reliable and standardized approach for flow cytometry (FC)-based MRD measurement and analysis is often missing.
Methods: Within the international AIEOP-BFM-ALL-FLOW study group we made a consensus on markers and a standard operating procedure for common 8- and 12-color T-ALL MRD panels.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!